Fallopian Tube Cancer — Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Citation(s)
A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers